Abbott Laboratories (ABT) Long-Term Deferred Tax (2009 - 2026)

Abbott Laboratories has disclosed Long-Term Deferred Tax across 16 years of filings, most recently posting $18.3 billion for Q2 2026.

• In Q2 2026, Long-Term Deferred Tax rose 5.86% year-over-year to $18.3 billion; the TTM figure through Jun 2026 stood at $18.3 billion (up 5.86% YoY), while the FY2025 annual figure was $18.4 billion, up 11.93% from the prior year.
• Long-Term Deferred Tax came in at $18.3 billion for Q2 2026 at Abbott Laboratories, roughly flat from $18.4 billion in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $18.4 billion in Q4 2025 to a low of $5.4 billion in Q2 2022.
• Average Long-Term Deferred Tax over 5 years is $10.8 billion, with a median of $7.6 billion recorded in 2024.
• Year-over-year, Long-Term Deferred Tax surged 131.91% in 2024 and rose 5.86% in 2026.
• Over 5 years, Long-Term Deferred Tax stood at $6.0 billion in 2022, then grew by 17.64% to $7.1 billion in 2023, then surged by 131.91% to $16.5 billion in 2024, then climbed by 11.93% to $18.4 billion in 2025, then retreated by 0.55% to $18.3 billion in 2026.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $18.3 billion in Q2 2026, $18.4 billion in Q1 2026, and $18.4 billion in Q4 2025.